06-29-2018 10:05 AM CET - Health & Medicine
Print

Worldwide Radiopharmaceuticals Market Size by focusing on Top Companies like Bayer AG, Positron Corporation, Avid Radiopharmaceuticals, Jubilant Pharma, Actinium Pharmaceuticals And Forecast till 2025

Press release from: Data Bridge Market Research
Radiopharmaceuticals Market 2025
Radiopharmaceuticals Market 2025


Radiopharmaceuticals Market Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.

The global radiopharmaceuticals market is fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market in order to sustain in long run. The report includes market shares of customer relation management market for global, Europe, North America, Asia Pacific and South America.

Request for Free Sample of “Global Radiopharmaceuticals Market” Report Visit @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Market Segmentation: Global Radiopharmaceuticals Market

The global market for radiopharmaceuticals by the following sub-categories is presented

1. By Type
o Diagnostic
o Therapeutic Radiopharmaceuticals

2. By Procedural Volume
o Diagnostic Procedures
 Single-Photon Emission Computed Tomography Radiopharmaceuticals
 Positron Emission Tomography Radiopharmaceuticals
I. Therapeutic Procedures
 Beta Emitters
 Alpha Emitters
 Brachy Therapy

3. By Application
Diagnostic Application
 Single-Photon Emission Computed Tomography
 Cardiology
 Lymphoma
 Thyroid
 Neurology
 Others
II. Positron Emission Tomography
 Oncology
 Cardiology
 Neurology
 Others
III. Therapeutic Application
 Thyroid
 Bone Metastasis
 Lymphoma
 Endocrine Tumors
 Others

4. By Sources
o Nuclear Reactors
o Cyclotrons

5. By End User
o Hospitals
o Ambulatory Surgical Centers
o Diagnostic Centers
o Cancer Research Institutes
o Others

6. By Geography
o North America
o South America
o Europe
o Asia-Pacific
o Middle East and Africa

Request for Table of Content of Full Report @ databridgemarketresearch.com/toc/?dbmr=global-radiopharma...

Advances in radiotracers and alpha radio immunotherapy-based targeted cancer treatment:

Radioisotopes therapy delivers the radiation directly in to the cancer cells. Radioisotopes are usually given as a capsule, drink or by injecting into the veins. Cancer cells absorb the radioactive substance more than the normal cells hence they receive the higher dose and this leads the cell to die. Depending on what type of cancer, different types of radioisotopes are used. Iodine 131 is used in thyroid cancer and in some rare cancer. Strontium-89 and samarium-153 is used in secondary bone cancer, they helps in reducing pain. Radium-223 is used to treat secondary bone cancer, and this is the new isotope therapy.

Including positron emission tomography (PET) and single photon emission computed tomography (SPECT) is included in molecular radiotracer imaging. This has the tremendous potential in diagnosis of the brain changes. An injection of radiolabeled compound is injected and goes through the regional distribution of the brain can be visualize 3dimentionally by PET or SPECT.
Radio tracers are mostly used in human epilepsy.

According to world nuclear association each year 40million of nuclear medicine procedures are performed. And the demand for radioisotopes is increasing by 5.0% annually. Around 10,000 hospitals use radioisotopes in medicines out of which 90.0% of radioisotopes is used for diagnosis. Technetium-99 is the most common radioisotope used with 40million procedures per month accounting for 80.0% of all nuclear medicine procedures worldwide.

According to World health organization 50 million of the peoples have epilepsy and nearly 80.0% of the people with epilepsy lives in low and middle income country.

According to national health survey and national survey for children health in 2014 the rate of epilepsy was 2.3 million in 2014 and that increases to 3 million by 2015. And in 2007 number of children suffering from epilepsy was 450,000 and that increases to 470,000 by 2015.

As per the data provided, the number of cases of cancer and epilepsy are expected to increase at a very higher rate, this means the use for radioisotopes as well as the radiotracers will be increased. This shows that the radiopharmaceuticals market will have a strong growing platform in future.
Some of the major market players in the global radiopharmaceuticals market are Cardinal Health., Mallinckrodt, General Electric Company, Lantheus Medical Imaging, Inc, Bayer AG, Bracco Imaging S.p.A, Nordion Inc., IBA, Jubilant Pharma. LLC, Modus Medical Devices Inc, Actinium Pharmaceuticals, Inc., Areva Pharma, Merck & Co., Inc, Navidea Biopharmaceuticals, Inc., Siemens Healthcare Private Limited, Eckert & Ziegler, Avid Bioservices, Inc, Alseres Pharmaceuticals, Inc, Alliance Medical Diagnostic Imaging Ltd.

Read more about Report Visit @ databridgemarketresearch.com/reports/global-radiopharmace...

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get 10% Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1103528 • Views: 678
More releasesMore releases

You can edit or delete your press release here: